Clinical Trial

Efficacy of Two HMOs in Chinese Infants

Recruiting
View on ClinicalTrials.gov →
Summary
This is a randomized, controlled, double-blind, intervention trial of healthy male and female term infants to evaluate the efficacy of the 2 HMOs on beneficially modulating the gut microbiota, gut maturation, gut barrier integrity, immune response, and other developmental outcomes in healthy Chinese infants. The trial consists of 2 randomized formula-fed groups, and a non-randomized breastfed reference group.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-08; most recent amendment 2025-11-26.
Status change: Not Yet Recruiting → Recruiting 2024-10-07
Trial Details
NCT Number NCT06361719
Lead Sponsor Société des Produits Nestlé (SPN)
Conditions Healthy Infants
Enrollment 262 participants
Start Date 2024-07-29
Primary Completion 2026-11 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-11-28